Averx Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 9.91 Cr
as on 13-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 7.48 Cr
as on 13-12-2024
- Revenue 209.54%
(FY 2021)
- Profit 69.93%
(FY 2021)
- Ebitda 165.67%
(FY 2021)
- Net Worth 67.39%
(FY 2021)
- Total Assets 14.92%
(FY 2021)
About Averx Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.91 Cr.
The company currently has active open charges totaling ₹7.48 Cr.
Srinivas Ramineni, Vns Kurapati, Dhana Tirupathi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100AP2014PTC095163
- Company No.
095163
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2014
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Averx Drugs Private Limited offer?
Averx Drugs Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Animal Medicines & Health Care, Anthelmintics, Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Averx Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagasekhar Ramineni  | Managing Director | 27-Mar-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivas Ramineni | Additional Director | 29-Jan-2024 | Current |
| Vns Kurapati | Director | 26-Aug-2014 | Current |
| Dhana Tirupathi | Director | 25-Apr-2015 | Current |
Financial Performance of Averx Drugs.
Averx Drugs Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 209.54% increase. The company also saw a substantial improvement in profitability, with a 69.93% increase in profit. The company's net worth Soared by an impressive increase of 67.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Averx Drugs?
In 2021, Averx Drugs had a promoter holding of 96.01% and a public holding of 3.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Sep 2018 | ₹2.13 Cr | Open |
Others Creation Date: 31 Aug 2016 | ₹5.35 Cr | Open |
How Many Employees Work at Averx Drugs?
Unlock and access historical data on people associated with Averx Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Averx Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Averx Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
